S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Shocking Bank Secret of the Ultra-Rich (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
The #1 Energy Passive Income Investment for 2023 (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
The Retirement of Your Dreams Awaits You… (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Shocking Bank Secret of the Ultra-Rich (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
The #1 Energy Passive Income Investment for 2023 (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
The Retirement of Your Dreams Awaits You… (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Shocking Bank Secret of the Ultra-Rich (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
The #1 Energy Passive Income Investment for 2023 (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
The Retirement of Your Dreams Awaits You… (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Shocking Bank Secret of the Ultra-Rich (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
The #1 Energy Passive Income Investment for 2023 (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
The Retirement of Your Dreams Awaits You… (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
NASDAQ:CODX

Co-Diagnostics (CODX) Stock Price, News & Analysis

$1.11
-0.02 (-1.77%)
(As of 02/28/2024 ET)
Today's Range
$1.11
$1.14
50-Day Range
$1.11
$1.50
52-Week Range
$0.98
$3.10
Volume
38,430 shs
Average Volume
48,460 shs
Market Capitalization
$33.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Co-Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
170.3% Upside
$3.00 Price Target
Short Interest
Bearish
1.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.10
Upright™ Environmental Score
News Sentiment
0.44mentions of Co-Diagnostics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.90) to ($1.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.52 out of 5 stars

Medical Sector

159th out of 958 stocks

Surgical & Medical Instruments Industry

22nd out of 97 stocks


CODX stock logo

About Co-Diagnostics Stock (NASDAQ:CODX)

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CODX Stock Price History

CODX Stock News Headlines

CODX Co-Diagnostics, Inc.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Co-Diagnostics Completes EUA Submission To FDA For Co-Dx PCR Pro
See More Headlines
Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
2/29/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CODX
Fax
N/A
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+170.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,240,000.00
Net Margins
-913.54%
Pretax Margin
-1,122.82%

Debt

Sales & Book Value

Annual Sales
$34.22 million
Cash Flow
$0.27 per share
Book Value
$3.70 per share

Miscellaneous

Free Float
29,847,000
Market Cap
$33.94 million
Optionable
Optionable
Beta
-0.63
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Dwight H. Egan (Age 71)
    Chairman, CEO & President
    Comp: $512.39k
  • Mr. Brian L. Brown CPA (Age 48)
    CFO & Company Secretary
    Comp: $387.52k
  • Dr. Brent C. Satterfield Ph.D. (Age 47)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $237.5k
  • Mr. Dan Bohrer CPA
    Vice President of Finance & Accounting
  • Dr. Mark Poritz Ph.D.
    Chief Scientific Officer
  • Mr. Andrew Benson
    Head of Investor Relations
  • Dr. Mayuranki Almaula
    Senior Vice President of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry
    Head of Commercialization LATAM/EUR
  • Ms. Ivory Chang
    Chief Regulatory Affairs Officer














CODX Stock Analysis - Frequently Asked Questions

Should I buy or sell Co-Diagnostics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CODX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CODX, but not buy additional shares or sell existing shares.
View CODX analyst ratings
or view top-rated stocks.

What is Co-Diagnostics' stock price target for 2024?

1 analysts have issued 12 month price objectives for Co-Diagnostics' stock. Their CODX share price targets range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 170.3% from the stock's current price.
View analysts price targets for CODX
or view top-rated stocks among Wall Street analysts.

How have CODX shares performed in 2024?

Co-Diagnostics' stock was trading at $1.33 at the beginning of 2024. Since then, CODX shares have decreased by 16.5% and is now trading at $1.11.
View the best growth stocks for 2024 here
.

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 475,700 shares, an increase of 32.3% from the January 31st total of 359,600 shares. Based on an average daily volume of 101,400 shares, the short-interest ratio is presently 4.7 days.
View Co-Diagnostics' Short Interest
.

When is Co-Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our CODX earnings forecast
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) issued its earnings results on Thursday, November, 11th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.17. The firm earned $30.10 million during the quarter, compared to analyst estimates of $24 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 29.02% and a negative net margin of 913.54%. During the same quarter in the prior year, the company earned $0.53 EPS.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional investors include Kestra Advisory Services LLC (0.45%), Physician Wealth Advisors Inc. (0.10%), SMI Advisory Services LLC (0.06%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Lee Brown, Eugene Durenard and Reed L Benson.
View institutional ownership trends
.

How do I buy shares of Co-Diagnostics?

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CODX) was last updated on 2/29/2024 by MarketBeat.com Staff